CELYAD SA (NASDAQ) was established in 2004, formerly known as Cardio3 BioSciences SA, and changed to its current name in May 2015. It is headquartered in Mont-Saint-Guibert, Belgium and has 80 full-time employees (12/31/2018). Clinical stage biopharmaceutical company, focusing on the development of CAR-T cell therapy.
Celyad SA (CYAD):
Celyad uses its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treat a series of solid and hematological tumors.
At present, Celyad’s main drug candidate product is only one-CYAD-01 (CAR-T NKG2D) has been evaluated in a phase I clinical trial to evaluate the effectiveness of multiple autologous CYAD-01 cells in 7 refractory cancers. Safety and clinical activity, including 5 solid tumors, such as colorectal cancer, ovarian cancer, bladder cancer, triple negative breast cancer and pancreatic cancer; 2 hematological tumors including acute myeloid leukemia and multiple myeloma.
Celyad SA (CYAD) investment:
Celyad is a company listed on Euronext in Brussels and Euronext in Paris. It submitted the Nasdaq IPO prospectus to the SEC on 5/18/2015 and landed on the US capital market on June 19, 2015. The issue price $ 68.56 , financing of 115 million US dollars, stock code: CYAD.
CYAD broke -20.41% on the first day of listing and closed at $54.57.